NovoCure Ltd — Director's Dealing 2021

Apr 9, 2021

SEC Form 4/A — Form 4/A

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-03-23

Reporting Person: Weinberg Uri (Chief Science Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-23	Ordinary Shares	S	2835	$140	Disposed	33471	Direct

Footnotes

F1: Amending original form 4 filed on March 25, 2021 to add additional transaction inadvertently omitted.

F2: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg.